- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Giant Eagle acquires Rx21 Specialty Pharmacy, enabling enhanced hepatitis C/organ transplant services
PRINCETON, N.J. — Bristol-Myers Squibb will present 22 study abstracts next month at the 62nd annual meeting of the American Association for the Study of Liver Diseases in San Francisco, the company said.
Key presentations set to take place at the meeting, called The Liver Meeting, include studies on the hepatitis B drug Baraclude (entecavir) and drugs under development for hepatitis C and liver cancer.
"Bristol-Myers Squibb is at the forefront of innovation in researching the treatment of liver diseases," Bristol-Myers Squibb SVP global development and medical affairs for research and development Brian Daniels said. "In hepatitis C, where there remains considerable unmet medical needs, our goal is to increase treatment options for patients by developing a portfolio of compounds with different mechanisms of action."